Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.79 |
| ▸ | ACHE | P22303 | 3/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.57 |
| ▸ | CLK1 | P49759 | 5/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.57 |
| ▸ | CLK2 | P49760 | 3/20 | 0.57 |
| ▸ | CLK3 | P49761 | 3/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685010 | 0.89 | CHUK (1.00) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL29986061 | 0.89 | CHUK (1.00) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL27098859 | 0.89 | ACHE (0.79) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL30667681 | 0.89 | ACHE (0.79) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL20483684 | 0.86 | CHUK (0.59) | CHUKACHEKDM4EALDH1A1HPGD | |
| SCHEMBL29533596 | 0.84 | KDM4E (0.68) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL2330779 | 0.84 | KDM4E (0.68) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL17520087 | 0.83 | CHUK (0.56) | CHUKDYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL30667654 | 0.81 | CHUK (0.54) | CHUKACHEDYRK1ACLK1CDK5 | |
| SCHEMBL24277835 | 0.79 | DYRK1A (0.60) | CHUKACHEDYRK1ACLK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111787945-B | Engineered nanovesicles as checkpoint blockers for cancer immunotherapy | 北卡罗莱纳州立大学 | 2024-11-29 | — | — | CN | claimed |
| CN-113782760-B | MOF material and preparation method thereof, proton exchange membrane and preparation method thereof, and fuel cell | 深圳氢时代新能源科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2022-04-28 | — | — | US | claimed |
| US-12622940-B2 | Combined fungal composition for modulating an inflammatory response | TURTLE BEAR HOLDINGS, LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-12622938-B2 | Compositions and methods for modulating inflammatory response | TURTLE BEAR HOLDINGS, LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
| US-10381578-B2 | Organometallic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-08-13 | — | — | US | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20060166978-A1 | Substituted beta carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2006-07-27 | — | — | US | disclosed |
| US-7026331-B2 | Substituted beta-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20040110759-A1 | Substituted beta carbolines | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-06-10 | — | — | US | disclosed |
| US-6627637-B2 | I kappa B kinase inhibitors for treating various disorders including arthritis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622940-B2 | Combined fungal composition for modulating an inflammatory response | SORD, ERG28, IL1B | CHUK 1036/4885ACHE 1166/4885DYRK1A 2997/4885 |
| US-20040110759-A1 | Substituted beta carbolines | CSNK1A1, CSNK2A1, CSNK2B | CHUK 52/4885ACHE 904/4885DYRK1A 2551/4885 |
| US-10381578-B2 | Organometallic compound and organic light-emitting device including the same | L1CAM, MSL1, CHRM1 | CHUK 3731/4885ACHE 961/4885DYRK1A 4546/4885 |
| US-12622938-B2 | Compositions and methods for modulating inflammatory response | IL1B, IL1R1, ERG28 | CHUK 1909/4885ACHE 1979/4885DYRK1A 2438/4885 |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | CHUK 2664/4885ACHE 32/4885DYRK1A 1663/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | CHUK 1412/4885ACHE 368/4885DYRK1A 711/4885 |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CHUK 2856/4885ACHE 40/4885DYRK1A 2215/4885 |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | CHUK 2779/4885ACHE 35/4885DYRK1A 1607/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CHUK 2664/4885ACHE 32/4885DYRK1A 1663/4885 |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CHUK 2664/4885ACHE 32/4885DYRK1A 1663/4885 |
| US-20060166978-A1 | Substituted beta carbolines | NFKBIA, RELA, IKBKG | CHUK 8/4885ACHE 2205/4885DYRK1A 3941/4885 |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CHUK 2664/4885ACHE 32/4885DYRK1A 1663/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CHUK 3444/4885ACHE 30/4885DYRK1A 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.